These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7249510)

  • 1. Isolation of peptides from uremic plasma that inhibit phenytoin binding to normal plasma proteins.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Aug; 30(2):276-80. PubMed ID: 7249510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation.
    Odar-Cederlof I
    Clin Pharmacokinet; 1977; 2(2):147-53. PubMed ID: 324689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.
    Olsen GD; Bennett WM; Porter GA
    Clin Pharmacol Ther; 1975 Jun; 17(6):677-84. PubMed ID: 1095281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma protein binding in uremia: extraction and characterization of an inhibitor.
    Depner TA; Gulyassy PF
    Kidney Int; 1980 Jul; 18(1):86-94. PubMed ID: 7218662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired plasma phenytoin binding in uremia. Effect of in vitro acidification and anion-exchange resin.
    Depner TA; Stanfel LA; Jarrard EA; Gulyassy PF
    Nephron; 1980; 25(5):231-7. PubMed ID: 7383235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrafiltration compared with equilibrium dialysis in the determination of unbound phenytoin in plasma.
    Koike Y; Magnusson A; Steiner E; Rane A; Sjöqvist F
    Ther Drug Monit; 1985; 7(4):461-5. PubMed ID: 3909538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered protein binding of diphenylhydantoin in uremic plasma.
    Blum MR; Riegelman S; Becker CE
    N Engl J Med; 1972 Jan; 286(2):109. PubMed ID: 5006870
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins.
    Dasgupta A; Malik S
    Am J Nephrol; 1994; 14(3):162-8. PubMed ID: 7977474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin.
    Shoeman DW; Azarnoff DL
    Pharmacology; 1972; 7(3):169-77. PubMed ID: 5054587
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of disease on binding of drugs to plasma proteins.
    Reidenberg MM; Affrime M
    Ann N Y Acad Sci; 1973 Nov; 226():115-26. PubMed ID: 4520390
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug protein binding in chronic renal failure: evaluation of nine drugs.
    Vanholder R; Van Landschoot N; De Smet R; Schoots A; Ringoir S
    Kidney Int; 1988 May; 33(5):996-1004. PubMed ID: 3392889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenytoin binding to partially purified albumin in renal disease.
    Kinniburgh DW; Boyd ND
    Clin Pharmacol Ther; 1981 Feb; 29(2):203-10. PubMed ID: 7460484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.